Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26564826 | 0.89 | PGK1 (0.32) | PGK1PGK2TAAR1CHRNA7 | |
| SCHEMBL27929264 | 0.85 | MBOAT4 (0.35) | MBOAT4PDE10AHCRTR1HCRTR2DGKZ | |
| SCHEMBL17658867 | 0.84 | MCHR1 (0.36) | TAAR1 | |
| SCHEMBL22181485 | 0.82 | PDE10A (0.37) | MBOAT4PDE10AHCRTR1HCRTR2DGKZ | |
| SCHEMBL19121330 | 0.81 | CHRNA7 (0.33) | TAAR1CHRNA7 | |
| SCHEMBL17658875 | 0.81 | MCHR1 (0.39) | TAAR1CHRNA7 | |
| SCHEMBL22181777 | 0.80 | PDE10A (0.39) | MBOAT4PDE10AHCRTR1HCRTR2DGKZ | |
| SCHEMBL17658874 | 0.78 | MCHR1 (0.41) | — | |
| SCHEMBL179528 | 0.78 | TAAR1 (0.42) | TAAR1 | |
| SCHEMBL24768969 | 0.77 | PDE8A (0.38) | PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11724997-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210053936-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9695198-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150368269-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724997-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | MBOAT4 2947/4885PDE10A 1592/4885HCRTR1 347/4885 |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | MBOAT4 3267/4885PDE10A 2092/4885HCRTR1 334/4885 |
| US-20210053936-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | MBOAT4 2947/4885PDE10A 1592/4885HCRTR1 347/4885 |
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | MBOAT4 3776/4885PDE10A 1347/4885HCRTR1 4453/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | MBOAT4 2964/4885PDE10A 1447/4885HCRTR1 770/4885 |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | MBOAT4 113/4885PDE10A 1269/4885HCRTR1 2952/4885 |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | MBOAT4 110/4885PDE10A 1339/4885HCRTR1 3249/4885 |
| US-20150368269-A1 | Factor IXa Inhibitors | F9, TFPI, F13B | MBOAT4 4299/4885PDE10A 1802/4885HCRTR1 3214/4885 |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | MBOAT4 3776/4885PDE10A 1347/4885HCRTR1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.